Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VEDOLIZUMAB Cause C-reactive protein increased? 466 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 466 reports of C-reactive protein increased have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.6% of all adverse event reports for VEDOLIZUMAB.

466
Reports of C-reactive protein increased with VEDOLIZUMAB
0.6%
of all VEDOLIZUMAB reports
157
Deaths
261
Hospitalizations

How Dangerous Is C-reactive protein increased From VEDOLIZUMAB?

Of the 466 reports, 157 (33.7%) resulted in death, 261 (56.0%) required hospitalization, and 90 (19.3%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 466 reports have been filed with the FAERS database.

What Other Side Effects Does VEDOLIZUMAB Cause?

Off label use (21,017) Colitis ulcerative (13,455) Crohn's disease (9,759) Drug ineffective (8,424) Diarrhoea (7,493) Abdominal pain (6,401) Fatigue (5,477) Haematochezia (5,215) Frequent bowel movements (4,527) Arthralgia (4,028)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which VEDOLIZUMAB Alternatives Have Lower C-reactive protein increased Risk?

VEDOLIZUMAB vs VELAGLUCERASE ALFA VEDOLIZUMAB vs VELCADE VEDOLIZUMAB vs VELETRI VEDOLIZUMAB vs VELIPARIB VEDOLIZUMAB vs VEMURAFENIB

Related Pages

VEDOLIZUMAB Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased VEDOLIZUMAB Demographics